418 results on '"Rotzinger, Susan"'
Search Results
2. Endocannabinoid concentrations in major depression: effects of childhood maltreatment and relation to hippocampal volume
3. Publisher Correction: Neuroanatomical dimensions in medication-free individuals with major depressive disorder and treatment response to SSRI antidepressant medications or placebo
4. Neuroanatomical dimensions in medication-free individuals with major depressive disorder and treatment response to SSRI antidepressant medications or placebo
5. AI-based dimensional neuroimaging system for characterizing heterogeneity in brain structure and function in major depressive disorder: COORDINATE-MDD consortium design and rationale
6. Depression-Anxiety Coupling Strength as a predictor of relapse in major depressive disorder: A CAN-BIND wellness monitoring study report
7. Atypical Brain Aging and Its Association With Working Memory Performance in Major Depressive Disorder
8. Assessing remission in major depressive disorder using a functional-structural data fusion pipeline: A CAN-BIND-1 study
9. A standardized workflow for long-term longitudinal actigraphy data processing using one year of continuous actigraphy from the CAN-BIND Wellness Monitoring Study
10. Resting-state EEG delta and alpha power predict response to cognitive behavioral therapy in depression: a Canadian biomarker integration network for depression study
11. An empirical analysis of structural neuroimaging profiles in a staging model of depression
12. Relation of hippocampal volume and SGK1 gene expression to treatment remission in major depression is moderated by childhood maltreatment: A CAN-BIND-1 report
13. Predicting recurrence of major depressive episodes using the Depression Implicit Association Test: A Canadian biomarker integration network in depression (CAN-BIND) report
14. Response trajectories during escitalopram treatment of patients with major depressive disorder
15. The course of insomnia symptoms during the acute treatment of major depressive disorder: A CAN-BIND-1 report
16. Response Inhibition and Predicting Response to Pharmacological and Cognitive Behavioral Therapy Treatments for Major Depressive Disorder: A Canadian Biomarker Integration Network for Depression Study
17. Alterations in the neural correlates of affective inhibitory control following cognitive behavioral therapy for depression: A Canadian biomarker integration network for depression (CAN-BIND) study
18. Rhythmicity of sleep and clinical outcomes in major depressive disorder: A CAN-BIND-1 report
19. Pain severity and pain interference during major depressive episodes treated with escitalopram and aripiprazole adjunctive therapy: a CAN-BIND-1 report
20. Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 study
21. Predicting escitalopram treatment response from pre-treatment and early response resting state fMRI in a multi-site sample: A CAN-BIND-1 report
22. Neuron-derived extracellular vesicles enriched from plasma show altered size and miRNA cargo as a function of antidepressant drug response
23. Structural covariance pattern abnormalities of insula in major depressive disorder: A CAN-BIND study report
24. Atypical brain aging and its association with working memory performance in major depressive disorder
25. Hypothalamus volume and DNA methylation of stress axis genes in major depressive disorder: A CAN-BIND study report
26. Metabolic variables associated with response to cognitive behavioural therapy for depression in females: A Canadian biomarker integration network for depression (CAN-BIND) study
27. White matter microstructure in youth at risk for serious mental illness: A comparative analysis
28. Atypical Brain Aging and Its Association With Working Memory Performance in Major Depressive Disorder
29. Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report
30. Cognitive Outcomes with Sequential Escitalopram Monotherapy and Adjunctive Aripiprazole Treatment in Major Depressive Disorder: A Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report
31. Functional neuroimaging biomarkers of anhedonia response to escitalopram plus adjunct aripiprazole treatment for major depressive disorder
32. Metabolomic signatures associated with depression and predictors of antidepressant response in humans: A CAN-BIND-1 report
33. Treatment-emergent and trajectory-based peripheral gene expression markers of antidepressant response
34. Association between the expression of lncRNA BASP-AS1 and volume of right hippocampal tail moderated by episode duration in major depressive disorder: a CAN-BIND 1 report
35. Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report
36. Hippocampal tail volume as a predictive biomarker of antidepressant treatment outcomes in patients with major depressive disorder: a CAN-BIND report
37. White Matter Indices of Medication Response in Major Depression: A Diffusion Tensor Imaging Study
38. Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response
39. Influence of CYP2C19, CYP2D6, and ABCB1 Gene Variants and Serum Levels of Escitalopram and Aripiprazole on Treatment-Emergent Sexual Dysfunction: A Canadian Biomarker Integration Network in Depression 1 (CAN-BIND 1) Study
40. Anxious arousal predicts within-person changes in hippocampal volume in adults with a history of childhood maltreatment: A CAN-BIND4 report.
41. Developing an Electroencephalography-Based Model for Predicting Response to Antidepressant Medication
42. GWAS-based machine learning approach to predict duloxetine response in major depressive disorder
43. The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot study
44. The Canadian Biomarker Integration Network in Depression (CAN-BIND): magnetic resonance imaging protocols
45. Influence of CYP2C19, CYP2D6, and ABCB1Gene Variants and Serum Levels of Escitalopram and Aripiprazole on Treatment-Emergent Sexual Dysfunction: A Canadian Biomarker Integration Network in Depression 1 (CAN-BIND 1) Study
46. GPR56/ADGRG1 is associated with response to antidepressant treatment
47. Pro-inflammatory markers are associated with response to sequential pharmacotherapy in major depressive disorder: a CAN-BIND-1 report
48. 286. Genetic Polymorphism of Brain-Derived Neurotrophic Factor is Related to Antidepressant Efficacy and Treatment-Induced Hippocampal Plasticity in Patients With Major Depressive Disorder: CAN-BIND-1 Study
49. AI-based dimensional neuroimaging system for characterizing heterogeneity in brain structure and function in major depressive disorder: COORDINATE-MDD consortium design and rationale.
50. AI-based dimensional neuroimaging system for characterizing heterogeneity in brain structure and function in major depressive disorder:COORDINATE-MDD consortium design and rationale
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.